Elisabeth Zinser

USPTO Granted Patents = 5 (Patent Applications = 2)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 8(Granted Patents)

Location History:

Erlangen, DE (2007 - 2012)
Buckenhof, DE (2015)
Marloffstein, DE (2014 - 2017)

Company Filing History:

4 out of 40

Argos Therapeutics, Inc.

patents

1 out of 832,812

Other

patents

Years Active: 2007-2017

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9732140 - Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases (2017-08-15),

2. 9102726 - Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same (2015-08-11),

3. 8759505 - Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases (2014-06-24),

4. 8124099 - Soluble CD83 proteins and use thereof for the treatment and prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells (2012-02-28),

5. 7169898 - Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells (2007-01-30),

Title: Elisabeth Zinser: Innovator in Immunology

Introduction

Elisabeth Zinser is a prominent inventor based in Marloffstein, Germany. She has made significant contributions to the field of immunology, particularly through her innovative research and patents. With a total of 5 patents, her work focuses on the treatment and prevention of diseases related to immune response dysfunction.

Latest Patents

Zinser's latest patents include groundbreaking inventions that utilize soluble forms of CD83 and nucleic acids encoding them. One of her notable inventions provides methods for using these soluble forms of CD83 to treat diseases caused by dysfunctional immune responses involving dendritic cells, T cells, and B cells. Additionally, she has developed soluble CD83 molecules specifically designed for therapeutic purposes, along with antibodies against these proteins and various assay methods and kits. Another patent outlines the use of nucleic acid recombination expression vectors encoding soluble forms of CD83, which can be used in pharmaceutical compositions and methods for producing these proteins.

Career Highlights

Throughout her career, Zinser has worked with various organizations, including Argos Therapeutics, Inc. Her research has significantly advanced the understanding of immune responses and has the potential to lead to new therapeutic strategies for treating immune-related diseases.

Collaborations

Zinser has collaborated with notable colleagues such as Alexander Steinkasserer and Matthias Lechmann. These partnerships have further enriched her research and contributed to her innovative work in the field.

Conclusion

Elisabeth Zinser's contributions to immunology through her patents and research highlight her role as a leading inventor in the field. Her work continues to pave the way for advancements in the treatment of immune-related diseases.

This text is generated by artificial intelligence and may not be accurate.